M.V. Ramana

CEO confirms launch of generic semaglutide in India at ~$14/month, holds first regulatory approval, and expects the Indian market to reach ~$1 billion. The company has filed for approvals in Canada, Brazil, Turkey, and other emerging markets. Patent expiry for GLP-1 drugs opens a vast, underpenetrated market in diabetes and obesity. Dr. Reddy's is an early mover with a fully integrated supply chain, a partnered ecosystem for patient support/nutrition, and a strategy to generate local clinical evidence. First-mover status in a high-growth generic segment, combined with a planned multi-country rollout, positions the company for significant new revenue streams. Intense price competition from other Indian generics erodes margins; regulatory delays in key export markets.